<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04307511</url>
  </required_header>
  <id_info>
    <org_study_id>2020PYN</org_study_id>
    <nct_id>NCT04307511</nct_id>
  </id_info>
  <brief_title>A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients</brief_title>
  <acronym>TIGER-diabetes</acronym>
  <official_title>A Randomized Controlled sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Tong Ren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Tong Ren Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigates try to confirm the hypothesis that low dose ticagrelor(60mg)
      had similar anti-platelets function compared with the standard dose ticagrelor in acute
      coronary syndrome patients with diabetes. Totally 60 ACS patients with diabetes will be
      divided into 3 groups randomly after PCI for one month. Group 1 will be treated with
      ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group; Group 2 will
      be treated with ticagrelor 90mg for 11 months after one month ticagreloar 90mg plus aspirin
      100 mg treatment after PCI; Group 3 will be treated with ticagrelor 60mg plus aspirin 100 mg
      for 11 months after one month standard DAPT treatment. The platelets function will be tested
      in VASP and TEG methods at 1 and 2 months after PCI as the primary endpoints.The clinical
      events will be observed 12 months after PCI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes of PRI detected by VASP</measure>
    <time_frame>changes of PRI from baseline (1 months after index PCI) to 2 months after index PCI</time_frame>
    <description>platelet reactivity index (PRI) detected by VASP (Vasodilator Stimulated Phosphoprotein) Phosphoprotein)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes of Maximum Amplitude (MA) detected by TEG</measure>
    <time_frame>changes of MA from baseline (1 months after index PCI) to 2 months after index PCI</time_frame>
    <description>Maximum Amplitude (MA) detected by TEG(Thromboelastography)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Coronary Syndrome Patients With Diabetes After PCI</condition>
  <arm_group>
    <arm_group_label>low dose DAPT therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard DAPT(ticagrelor 90mg plus aspirin 100 mg )treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard dose DAPT therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treated with ticagrelor 90mg for 11 months after one month ticagreloar 90mg plus aspirin 100 mg treatment after PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>60mg ticagrelor based DAPT vs 90mg ticagrelor based DAPT vs 90mg ticagrelor monotherapy</description>
    <arm_group_label>low dose DAPT therapy</arm_group_label>
    <arm_group_label>monotherapy</arm_group_label>
    <arm_group_label>standard dose DAPT therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin</description>
    <arm_group_label>low dose DAPT therapy</arm_group_label>
    <arm_group_label>monotherapy</arm_group_label>
    <arm_group_label>standard dose DAPT therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be at least 18 years of age and less than 90 years old

          2. Patients should have undergone successful percutaneous coronary intervention with
             drug-eluting stent for acute coronary syndrome with diabetes mellitus.

          3. Subject understand the study requirements and the treatment procedures and

          4. provided informed consent before the procedure

        Exclusion Criteria:

          1. Female of childbearing potential, unless a recent pregnancy test is negative, who
             possibly plan to become pregnant any time after enrollment into this study

          2. Active bleeding

          3. Known hypersensitivity or contraindication to study medications

          4. Female of childbearing potential, unless a recent pregnancy test is negative, who
             possibly plan to become pregnant any time after enrollment into this study

          5. Non-cardiac co-morbid conditions are present with life expectancy &lt;2 year or that may
             result in protocol non-compliance (per site investigator's medical judgment).

          6. Subjects with Cerebral hemorrhage history

          7. Subjects with stroke history in half a year

          8. subjects with active malignant tumor

          9. subjects with whom oral anticoagulants are needed

         10. Other conditions which the investigators think not applicable to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lei Hou, Doctor</last_name>
    <phone>13564868096</phone>
    <email>Dr_houlei@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>shanghai Tongren hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200336</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Hou, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 8, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>April 26, 2020</last_update_submitted>
  <last_update_submitted_qc>April 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Tong Ren Hospital</investigator_affiliation>
    <investigator_full_name>Hou Lei</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

